ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Support for increased FDA funding
| Lobbyist | Covered position, as disclosed |
|---|---|
| REGINIA GRAYSON BENJAMIN | — |
| ADAM PARKER NELSON | — |
Medicare/Medicaid MMM
21st century cures (HR 6), Medicare Part D pharmacy drug management programs for at-risk beneficiaries (S. 1913),Biosimilar naming, Medicare Part D, AMCP draft legislation - "Medicare Prescription Drug Anti-Fraud Act", Medicare Part B reimbursement of biosimilars, Senate Innovations Initiative and Medication Therapy Management (MTM)
| Lobbyist | Covered position, as disclosed |
|---|---|
| REGINIA GRAYSON BENJAMIN | — |
| ADAM PARKER NELSON | — |
Pharmacy PHA
Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| REGINIA GRAYSON BENJAMIN | — |
| ADAM PARKER NELSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.